Zymeworks (ZYME) Form 144 shows insider sell request of 31,641 shares

Rhea-AI Filing Summary

Zymeworks filed a Form 144 reporting a proposed sale of 31,641 shares of common stock on 02/17/2026, tied to the exercise of options and an exercise-and-sell-to-cover transaction.

The excerpt also lists prior sales by Leone Patterson of 6,832 shares on 01/12/2026 for $154,905.35 and 117,255 shares on 02/13/2026 for $2,706,749.60.

Insights

Securities Compliance Attorney

Form 144 documents a proposed resale tied to option exercise and sell-to-cover.

The filing lists a proposed sale of 31,641 shares on 02/17/2026, described as an exercise of options with an exercise-and-sell-to-cover method. This is a routine disclosure under resale rules and identifies past reported dispositions by a named holder.

Timing and settlement mechanics beyond the stated are not shown; cash‑flow treatment to the issuer is not specified in the excerpt. Subsequent SEC filings or broker confirmations would show completion details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1 New York Plaza, 38th Floor, New York NY 10004	31641	715086.60	74836534	02/17/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/17/2026	Exercise of options	Issuer			31641	02/17/2026	Exercise and sell to cover

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Leone Patterson c/o Zymeworks Inc. 108 Patriot Drive, Suite A Middletown DE 19709	Common Stock	01/12/2026	6832	154905.35
Leone Patterson c/o Zymeworks Inc. 108 Patriot Drive, Suite A Middletown DE 19709	Common Stock	02/13/2026	117255	2706749.60

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ZYME's Form 144 report?

The filing reports a proposed resale of 31,641 shares on 02/17/2026, described as an exercise of options with an exercise‑and‑sell‑to‑cover method, per the excerpt provided.

Who sold shares previously according to the excerpt?

The excerpt shows Leone Patterson sold 6,832 shares on 01/12/2026 for $154,905.35 and 117,255 shares on 02/13/2026 for $2,706,749.60.

Does the Form 144 indicate proceeds go to Zymeworks?

The excerpt does not state proceeds treatment; it lists the proposed resale method as an exercise-and-sell-to-cover transaction but does not assign cash receipts to the issuer in the provided text.

What is the primary transaction date shown?

The primary proposed sale date in the excerpt is 02/17/2026, associated with the reported 31,641 shares to be sold via exercise of options.

Are the listed past sales part of the current offering?

The past dispositions by Leone Patterson are reported as sales on 01/12/2026 and 02/13/2026; they are historical transactions listed in the excerpt and not described as part of the proposed 02/17/2026 resale.